Knotnerus Tim Jasper, the Chief Executive Officer of AgomAb Therapeutics NV, has made significant stock acquisitions, purchasing a total of 11,000 shares over two days. This move is seen as a strong indicator of his confidence in the company’s future prospects.
The transactions took place on October 5 and October 6, 2026, with Jasper acquiring 6,000 shares at $8.48 each and 5,000 shares at $8.70 each. Following these acquisitions, Jasper now owns a total of 34,394 shares of AgomAb Therapeutics, reflecting a substantial personal investment in the company.
Background
AgomAb Therapeutics NV, identified by the Central Index Key (CIK) 0002020932, operates in the biological products sector, specifically focusing on products that do not involve diagnostic substances. The company is incorporated in C9 and has its business address in Antwerpen, Belgium. The recent filings indicate a commitment to transparency in ownership changes, with the latest filing dated October 7, 2026.
What the Filing Says
The filing reveals that Jasper reported his stock transactions under Form 4, which is used to disclose changes in ownership. The report states, "The common shares may be represented by American Depositary Shares, each of which currently represents one common share." This indicates that the shares Jasper acquired are likely linked to broader trading mechanisms in the market.
Impact
Jasper's stock acquisitions may influence investor perception and confidence in AgomAb Therapeutics, especially among stakeholders and potential investors. His actions could signal a positive outlook for the company, which operates in a competitive landscape of biological products.
What's Next
The filing does not say what happens next.